Published in J Neurosci on November 14, 2012
APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep (2015) 1.02
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci (2013) 0.92
Turnover of C99 is controlled by a crosstalk between ERAD and ubiquitin-independent lysosomal degradation in human neuroglioma cells. PLoS One (2013) 0.90
MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease. Cell Mol Life Sci (2015) 0.88
Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin Invest (2016) 0.87
Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters. Peptides (2013) 0.86
A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One (2015) 0.84
Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease. PLoS One (2013) 0.83
Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology. Acta Neuropathol (2016) 0.82
Early hyperactivity in lateral entorhinal cortex is associated with elevated levels of AβPP metabolites in the Tg2576 mouse model of Alzheimer's disease. Exp Neurol (2014) 0.82
Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1-MMP. Front Aging Neurosci (2014) 0.82
Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease. ACS Chem Neurosci (2013) 0.82
Can BACE1 inhibition mitigate early axonal pathology in neurological diseases? J Alzheimers Dis (2014) 0.80
Proliferation, differentiation and amyloid-β production in neural progenitor cells isolated from TgCRND8 mice. Neuroscience (2013) 0.79
Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer's disease. Acta Neuropathol Commun (2014) 0.78
The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. Mol Psychiatry (2016) 0.77
Loss of presenilin function is associated with a selective gain of APP function. Elife (2016) 0.77
Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model. PLoS One (2015) 0.77
Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages. Neuroscience (2015) 0.77
A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. J Biol Chem (2016) 0.77
Structure of the transmembrane domain of human nicastrin-a component of γ-secretase. Sci Rep (2016) 0.76
Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-κB/BACE1 Signaling Pathways. PLoS One (2016) 0.75
Expression of B4GALNT1, an essential glycosyltransferase for the synthesis of complex gangliosides, suppresses BACE1 degradation and modulates APP processing. Sci Rep (2016) 0.75
MT5-MMP Promotes Alzheimer's Pathogenesis in the Frontal Cortex of 5xFAD Mice and APP Trafficking in vitro. Front Mol Neurosci (2017) 0.75
Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein. Mol Psychiatry (2016) 0.75
Aβ42 oligomers modulate β-secretase through an XBP-1s-dependent pathway involving HRD1. Sci Rep (2016) 0.75
Evaluation of the amyloid beta-GFP fusion protein as a model of amyloid beta peptides-mediated aggregation: a study of DNAJB6 chaperone. Front Mol Neurosci (2015) 0.75
Exosomes in the Diseased Brain: First Insights from In vivo Studies. Front Neurosci (2017) 0.75
Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer's disease. Sci Adv (2017) 0.75
Precocious Alterations of Brain Oscillatory Activity in Alzheimer's Disease: A Window of Opportunity for Early Diagnosis and Treatment. Front Cell Neurosci (2015) 0.75
Localization and Processing of the Amyloid-β Protein Precursor in Mitochondria-Associated Membranes. J Alzheimers Dis (2016) 0.75
Experimental microembolism induces localized neuritic pathology in guinea pig cerebrum. Oncotarget (2015) 0.75
Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer's disease: Alleviation by pantethine. PLoS One (2017) 0.75
Physiological and pathophysiological control of synaptic GluN2B-NMDA receptors by the C-terminal domain of amyloid precursor protein. Elife (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun (1984) 8.14
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci (2007) 5.72
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 4.51
Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron (2005) 3.83
Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One (2010) 3.62
Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature (1992) 3.22
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem (2010) 3.16
Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron (2006) 2.88
Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science (1992) 2.82
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature (2010) 2.80
The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci (2009) 2.80
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol (2000) 2.78
Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain (2011) 2.76
Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci (2006) 2.57
TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature (2006) 2.56
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature (1997) 2.44
Autophagy failure in Alzheimer's disease--locating the primary defect. Neurobiol Dis (2011) 2.14
The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J Cell Sci (2004) 2.07
Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging (2005) 2.06
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2005) 2.05
Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci (2003) 1.91
The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem Res (2000) 1.84
Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem (1995) 1.83
Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int J Biochem Cell Biol (2004) 1.74
Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci U S A (1990) 1.66
Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One (2011) 1.62
The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci (1993) 1.61
Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci (2010) 1.60
Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol (2005) 1.59
Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A (2009) 1.57
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther (2009) 1.51
Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49
Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci (2004) 1.46
Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci (2012) 1.45
Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci (2008) 1.44
New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat Cell Biol (2001) 1.40
Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci (2007) 1.39
Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci (2009) 1.35
Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J Biol Chem (2007) 1.35
Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem (2002) 1.34
Retracted Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci (2011) 1.31
Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci (2006) 1.29
Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep (2008) 1.27
The physiology of the β-amyloid precursor protein intracellular domain AICD. J Neurochem (2011) 1.26
Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci (2009) 1.26
Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci (1996) 1.25
The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem (2010) 1.21
Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci (2010) 1.20
β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med (2012) 1.20
Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One (2011) 1.17
Alzheimer's disease and the amyloid β-protein. Prog Mol Biol Transl Sci (2012) 1.16
Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun (2004) 1.16
Presenilin 1 mutations activate gamma 42-secretase but reciprocally inhibit epsilon-secretase cleavage of amyloid precursor protein (APP) and S3-cleavage of notch. J Biol Chem (2002) 1.15
alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. J Neurochem (2009) 1.15
Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis (2009) 1.05
Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem (2003) 1.04
Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiol Dis (2007) 1.02
The role of the endosomal/lysosomal system in amyloid-beta production and the pathophysiology of Alzheimer's disease: reexamining the spatial paradox from a lysosomal perspective. J Alzheimers Dis (2004) 1.02
Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J Biol Chem (2000) 1.02
The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis. Biochem Biophys Res Commun (2006) 1.01
Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease? J Neurosci Res (2012) 0.99
Evidence that the amyloid-β protein precursor intracellular domain, AICD, derives from β-secretase-generated C-terminal fragment. J Alzheimers Dis (2012) 0.98
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One (2010) 0.97
BACE1- and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors. J Biol Chem (2003) 0.95
APPepsilon, the epsilon-secretase-derived N-terminal product of the beta-amyloid precursor protein, behaves as a type I protein and undergoes alpha-, beta-, and gamma-secretase cleavages. J Neurochem (2006) 0.94
Memory impairment and cholinergic dysfunction by centrally administered Abeta and carboxyl-terminal fragment of Alzheimer's APP in mice. FASEB J (2001) 0.92
TMP21 transmembrane domain regulates gamma-secretase cleavage. J Biol Chem (2009) 0.90
AICD nuclear signaling and its possible contribution to Alzheimer's disease. Curr Alzheimer Res (2012) 0.88
Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. Mt Sinai J Med (2010) 0.87
AβPP accumulation and/or intraneuronal amyloid-β accumulation? The 3xTg-AD mouse model revisited. J Alzheimers Dis (2012) 0.85
An etiological role of amyloidogenic carboxyl-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. J Neurochem (1997) 0.84
Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity. J Neurochem (2009) 0.83
Neprilysin activity and expression are controlled by nicastrin. J Neurochem (2006) 0.83
An alternative metabolic pathway of amyloid precursor protein C-terminal fragments via cathepsin B in a human neuroglioma model. FASEB J (2011) 0.81